Skip Navigation



Nucleic Acids Research Advance Access published online on October 21, 2008

Nucleic Acids Research, doi:10.1093/nar/gkn666
This Article
Right arrow Full Text Freely available
Right arrow Print PDF (3724K) Freely available
Right arrow Screen PDF (592K) Freely available
Right arrow Supplementary Data
Right arrowOA All Versions of this Article:
36/20/6608    most recent
gkn666v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Gatto, G.
Right arrow Articles by Mallardo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gatto, G.
Right arrow Articles by Mallardo, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Molecular Biology

Epstein–Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-{kappa}B pathway

Graziana Gatto, Annalisa Rossi, Daniela Rossi, Sven Kroening, Stefano Bonatti and Massimo Mallardo*

Department of Biochemistry and Medical Biotechnologies, University of Naples Federico II, Naples, Italy

*To whom correspondence should be addressed. Tel: +39 081 7463627; Fax: +39 081 7463205; Email: mallardo{at}dbbm.unina.it

Received August 8, 2008. Revised September 15, 2008. Accepted September 21, 2008.

The Epstein–Barr virus (EBV)-encoded latent membrane protein-1 (LMP1), a functional homologue of the tumor necrosis factor receptor family, substantially contributes to EBV's oncogenic potential by activating nuclear factor-{kappa}B (NF-{kappa}B). miR-155 is an oncogenic miRNA critical for B-cell maturation and immunoglobulin production in response to antigen. We report that miR-155 expression is much higher in EBV-immortalized B cells than in EBV-negative B cells. LMP1, but not LMP2, up-regulated the expression of miR-155, when transfected in EBV-negative B cells. We analyzed two putative NF-{kappa}B binding sites in the miR-155 promoter; both sites recruited NF-{kappa}B complex, in nuclear extract from EBV-immortalized cells. The exogenous expression of LMP1, in EBV-negative background, is temporally correlated to induction of p65 with binding on both NF-{kappa}B sites and with miR-155 overexpression. The induction of p65 binding together with increased RNA polymerase II binding, confirms that LMP1-mediated activation of miR-155 occurs transcriptionally. In reporter assays, miR-155 promoter lacking NF-{kappa}B binding sites was no longer activated by LMP1 expression and an intact AP1 site is needed to attain maximum activation. Finally, we demonstrate that LMP1-mediated activation of miR-155 in an EBV-negative background correlates with reduction of protein PU.1, which is a possible miR target.


Present address: Sven Kroening, Universitätsklinikum Erlangen, Medizinische Klinik 4, Erlagen, DE, Germany

The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BloodHome page
Y. Yamanaka, H. Tagawa, N. Takahashi, A. Watanabe, Y.-M. Guo, K. Iwamoto, J. Yamashita, H. Saitoh, Y. Kameoka, N. Shimizu, et al.
Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia
Blood, October 8, 2009; 114(15): 3265 - 3275.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.